Printer Friendly

AGOURON PHARMACEUTICALS NAMES FORMER PRESIDENT OF MERCK INTERNATIONAL TO BOARD

 AGOURON PHARMACEUTICALS NAMES FORMER PRESIDENT
 OF MERCK INTERNATIONAL TO BOARD
 SAN DIEGO, March 19 /PRNewswire/ -- Agouron Pharmaceuticals Inc. (NASDAQ-NMS: AGPH) today announced the election of A.E. Cohen to its board of directors.
 In January 1992, Cohen concluded a 34-year career with Merck & Co. Inc. where he most recently held the positions of senior vice president and president of Merck Sharpe and Dohme International.
 "Mr. Cohen brings an incomparable level of international experience in the global pharmaceutical industry," said Peter Johnson, president and chief executive officer of Agouron. "His perspective and involvement are certain to be of great value as Agouron sets and executes its strategy for worldwide development and commercialization of therapeutic products."
 Cohen will replace Theodor Heinrichs, who has retired from Agouron's board of directors after eight years of service.
 Agouron Pharmaceuticals Inc. is a pioneer and leader of a new technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases.
 -0- 3/19/92
 /CONTACT: Peter Johnson, president and CEO, or Donna Nichols, of Agouron Pharmaceuticals, 619-622-3000/
 (AGPH) CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: PER


DM-EH -- SD001 -- 9529 03/19/92 09:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:225
Previous Article:CBLX HOLDINGS INC. ANNOUNCES THE ACQUISITION OF ARIZONA VIDEO DUPLICATION INC.
Next Article:ORTHOFIX INTERNATIONAL N.V. FILES REGISTRATION STATEMENT WITH THE SEC
Topics:


Related Articles
AGOURON NAMES VICE PRESIDENT AND GENERAL COUNSEL
AGOURON NAMES VICE PRESIDENT AND GENERAL COUNSEL
C O R R E C T I O N -- AGOURON PHARMACEUTICALS.
TWO NEW MEMBERS TO JOIN BOARD OF FOUNTAIN PHARMACEUTICALS
AGOURON PHARMACEUTICALS NAMES FORMER EXECUTIVE VICE PRESIDENT OF MARION LABORATORIES TO BOARD
AGOURON PHARMACEUTICALS NAMES ONCOLOGY ADVISORY BOARD
THE UPJOHN COMPANY SELECTS CHAIRMAN AND CHIEF EXECUTIVE OFFICER
Agouron Completes Management Changes
Merck KGaA Names Engle New Generics Group Regional Director, North America.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters